Long acting GLP-1 receptor agonist (injectable)
Polyethylene glycol loxenatide injection
PEGLOX_SC
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.79 (-1.19 to -0.40) | 0.46 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -11.69 (-15.59 to -7.78) | 0.99 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 4.51 (1.51 to 13.27) | 0.57 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.05 (0.00 to 1.11) | 0.76 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.46 (0.02 to 10.76) | 0.78 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.07 (0.00 to 1.61) | 0.90 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -4.40 (-8.53 to -0.14) | 0.80 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 12.20 (2.82 to 49.50) | 0.89 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 15.37 (3.49 to 54.89) | 0.84 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.07 (0.20 to 6.78) | 0.47 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.92 (0.22 to 3.99) | 0.62 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.23 (1.76 to 17.42) | 0.19 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 4.29 (0.90 to 28.74) | 0.29 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.94 (0.28 to 3.30) | 0.64 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.66 (0.04 to 11.75) | 0.45 |